<DOC>
	<DOC>NCT01269476</DOC>
	<brief_summary>This is a randomised, double-blind, group-sequential, placebo-controlled, safety and pharmacokinetic study in healthy, aged volunteers. Objectives: 1. to confirm the previously reported safety profile of oral SNX-001 after single and multiple doses of 3.6, 7.2 or 10.8 mg compared to placebo 2. to establish SNX-001 pharmacokinetic profile.</brief_summary>
	<brief_title>Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers</brief_title>
	<detailed_description>This study is an exploratory study designed as a group sequential single and multiple escalating dose, double-blind within cohort, randomized, placebo controlled study to investigate the safety and tolerability as well as the pharmacokinetics and pharmacodynamics of SNX-001 given as oral doses in aged volunteers.</detailed_description>
	<mesh_term>Methanesulfonyl fluoride</mesh_term>
	<criteria>Healthy males or females Physically and mentally healthy subjects Body weight &gt;60 kg and body weight â‰¤ 100 kg Evidence of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, haematological, psychiatric, neurological or other significant acute or chronic abnormalities History of general malignant diseases Evidence of myasthenic weakness Acute infection or any other febrile illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>